Agenus Stock More Than Doubles on $85 Million Private Placement to Fund Colon Cancer Trial

Shares of Agenus (AGEN) surged more than 110% in morning trading after the immuno-oncology firm announced a significant private placement financing. The deal provides crucial funding for a late-stage clinical trial of its promising combination cancer therapy.

Financing and Strategic Shift

Agenus secured approximately $85 million in upfront gross proceeds through an oversubscribed private placement, according to a company announcement. The financing, led by Commodore Capital with participation from RA Capital Management and others, includes purchase warrants that could increase the total proceeds to $340 million if fully exercised.

In a strategic pivot, Agenus will use the funds for its registrational Phase 3 ROBBIN trial. Consequently, the company will discontinue financial support for its BATTMAN Phase 3 study in late-line metastatic colorectal cancer. This move concentrates resources on the earlier-stage neoadjuvant opportunity, where its Phase 2 data has shown strong responses.

Market Reaction and Outlook

Investors reacted positively to the news, which addresses a persistent concern about the company's funding. The transaction was priced at a premium to the previous closing price, and the potential for a fully funded cash runway through 2031 significantly de-risks the company's financial position.

Ad

The stock's rally stood in stark contrast to the broader market, with both the S&P 500 and Nasdaq trading lower. This indicates the move was driven entirely by the company-specific news, reflecting a sharp reassessment of Agenus's ability to advance its lead clinical program.

Focus on Colon Cancer Trial

The financing is earmarked for the 850-patient ROBBIN study, which will evaluate the combination of botensilimab and balstilimab (BOT+BAL) as a neoadjuvant treatment for microsatellite-stable (MSS) colon cancer.

This is a significant commercial opportunity, as no new therapies have been approved in this disease setting for over two decades. Agenus estimates the U.S. addressable market for this indication is more than $7 billion annually.